Atossa Therapeutics, Inc

(NASDAQ:ATOS)

Latest On Atossa Therapeutics, Inc (ATOS):

Date/Time Type Description Signal Details
2023-03-22 23:50 ESTNewsAtossa Therapeutics GAAP EPS of -$0.21 beats by $0.01N/A
2023-02-28 16:56 ESTNewsAtossa Therapeutics FY 2022 Earnings PreviewN/A
2023-02-13 17:16 ESTNewsAtossa announces new U.S. patent covering lead assetN/A
2022-11-08 08:22 ESTNewsAtossa Therapeutics GAAP EPS of -$0.06 in-lineN/A
2022-11-01 22:41 ESTNewsAtossa acquiring ~20% stake in Dynamic Cell Therapies to boost CAR-T developmentN/A
2022-10-24 18:54 ESTNewsAtossa receives FDA OK to begin phase 2 trial of (Z)-endoxifen for breast cancerN/A
2022-10-11 12:37 ESTNewsAtossa Therapeutics: Still Gets An 'Incomplete' RatingN/A
2022-08-08 19:55 ESTNewsAtossa Therapeutics GAAP EPS of -$0.05N/A
2022-06-06 16:58 ESTNewsClover Health, Aurinia Pharma among the top 10 health care additions to Russell 3000 Index, Asensus Surgical, Clovis Oncology among top deletionsN/A
2022-05-10 02:23 ESTNewsAtossa Therapeutics GAAP EPS of -$0.04 beats by $0.02N/A
2022-04-21 01:18 ESTNewsAtossa rebounds after enrollment update on study for COVID-19 therapyN/A
2022-03-09 03:27 ESTNewsAtossa Therapeutics issued patent covering breast cancer therapy endoxifenN/A
2022-03-01 03:13 ESTNewsAtossa Therapeutics GAAP EPS of -$0.18N/A
2021-12-10 10:39 ESTNewsA First Assessment On Atossa TherapeuticsN/A
2021-11-15 21:01 ESTNewsAtossa Therapeutics EPS beats by $0.02N/A
2021-10-01 08:19 ESTNewsAtossa starts enrollment in early-stage trial for COVID-19 therapy targeting long-haulersN/A
2021-09-22 21:41 ESTNewsAtossa Therapeutics: Diversification Into COVID Makes Sense In A Variants WorldN/A
2021-09-02 15:07 ESTNewsAtossa Therapeutics gets approval for mid-stage Endoxifen MBD trial in SwedenN/A
2021-08-14 05:43 ESTNewsAtossa Therapeutics EPS misses by $0.02N/A
2021-07-31 05:09 ESTNewsAtossa falls 10% after convening a special meeting for shareholdersN/A
2021-07-31 05:09 ESTNewsERYTECH Pharma, Allied Healthcare Products leads healthcare gainers; Intec Pharma, Translate Bio among major losersN/A
2021-07-30 09:56 ESTNewsAtossa loses a tenth after convening a special meeting for shareholdersN/A
2021-07-20 19:59 ESTNewsAtossa reaches a two-year high ahead of data readout for breast cancer therapyN/A
2021-07-20 19:58 ESTNewsAtossa Therapeutics shares fall after mid-stage Endoxifen breast cancer study resultsN/A
2021-07-20 19:55 ESTNewsAtossa Therapeutics to be included in the Russell 2000, 3000 indexesN/A
2021-07-20 19:51 ESTNewsAtossa Therapeutics continues rally amid a series of catalystsN/A
2021-07-20 19:45 ESTNewsQuant System Highlight: Investors Following This Are Up 120% In A Month! (Video)N/A
2021-07-20 19:44 ESTNewsAtossa rallies ahead of inclusion in Russell IndexesN/A
2021-07-20 19:43 ESTNewsArcus Bio ranks in top weekly healthcare gainers amid positive domvanalimab data; Biogen hit by Lilly donanemab Breakthrough Therapy tagN/A
2021-07-20 19:39 ESTNewsAtossa Therapeutics: Hope Springs EternalN/A
2021-07-20 19:36 ESTNewsCassava, Annovis among H1 biotech winners while Grayburg, Odonate biggest laggardsN/A
2021-07-20 19:33 ESTNewsAtossa Therapeutics gets regulatory nod for AT-H201 COVID-19 study in AustraliaN/A
2021-07-20 19:27 ESTNewsAtossa Therapeutics: Bear Market Defying Biotech Running Out Of UpsideN/A
2021-07-20 19:26 ESTNewsAtossa in selloff for second straight session after sharp run-up this yearN/A
2021-07-20 19:26 ESTNewsFreeline Therapeutics, Cytokinetics leads healthcare gainers; China SXT Pharmaceuticals, Atossa Therapeutics among major losersN/A
2021-04-17 03:15 ESTNewsAtossa Therapeutics Finds Its Share Price Drifting Between CatalystsN/A
2021-04-09 00:34 ESTNewsAtossa Therapeutics says ovarian cancer patient begins treatment with oral endoxifenN/A
2021-03-31 17:04 ESTNewsAtossa Therapeutics EPS misses by $0.76N/A
2021-03-22 22:55 ESTNewsAtossa Therapeutics prices $50M direct offering; shares fallN/A
2021-03-11 23:43 ESTNewsAtossa gets FDA safe to proceed letter for endoxifen in an ovarian cancer patientN/A
2021-02-25 20:05 ESTNewsAtossa climbs after announcing early-stage data for COVID-19 nasal sprayN/A
2021-02-11 03:16 ESTNewsAtossa hints at potential pipeline additions, provides 2021 strategyN/A
2021-02-10 07:12 ESTNewsZomedica, Nemaura and Senseonics extend premarket gainsN/A
2021-02-06 14:45 ESTNewsAssessing Atossa TherapeuticsN/A
2021-02-04 09:55 ESTNewsAtossa updates on single-patient study for EndoxifenN/A
2021-02-02 22:07 ESTNewsAtossa halts Endoxifen breast cancer study after positive dataN/A
2021-01-06 17:26 ESTNewsAtossa Therapeutics prices ~$25M direct offering, stock -23% PMN/A
2021-01-02 15:09 ESTFinancialsCompany financials have been released.Neutral
2020-12-17 13:49 ESTNewsAtossa Therapeutics prices $14M registered direct offeringN/A
2020-12-13 03:15 ESTFinancialsCompany financials have been released.Neutral

About Atossa Therapeutics, Inc (ATOS):

Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.

ATOS Quotes by TradingView

See Advanced Chart

General

  • Name Atossa Therapeutics, Inc
  • Symbol ATOS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 4
  • Last Split Factor1:12
  • Last Split Date2018-04-20
  • Fiscal Year EndDecember
  • IPO Date2012-11-08
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryHealth Care Equipment
  • Web URLhttp://atossatherapeutics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 21.03
  • Enterprise Value EBITDA 0.09
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.36
  • Return on Assets -58%
  • Return on Equity -104%
  • Earnings Per Share -$2.51
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 193.97 million
  • EBITDA -16713626
  • Analyst Target Price $6.25
  • Book Value Per Share $0.88
View More

Share Statistics

  • Shares Outstanding 71.57 million
  • Shares Float 9.37 million
  • % Held by Insiders 12%
  • % Held by Institutions 6.49%
  • Shares Short 7.06 million
  • Shares Short Prior Month 5.76 million
  • Short Ratio 0.21
  • Short % of Float 10%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 2.16
  • 52 Week High $5.08
  • 52 Week Low $0.81
  • 50 Day Moving Average 2.95
  • 200 Day Moving Average 2.01
View More

Dividends

  • Dividend Date 2018-04-20
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Atossa Therapeutics, Inc (ATOS) Dividend Calendar:

ATOS's last dividend payment was made to shareholders on April 20, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Atossa Therapeutics, Inc (ATOS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.34-$0.351.45%
2020-06-302020-08-13$N/A-$0.43-$0.28-53.57%
2020-03-312020-05-13$N/A-$0.32-$0.3917.95%
2019-12-312020-03-26$N/A-$0.26-$0.3321.21%
2019-09-302019-11-13$N/A-$0.36-$0.5230.77%
2019-06-302019-08-13$N/A-$0.80-$0.48-66.67%
2019-03-312019-05-13$N/A-$0.62
2018-12-312019-03-28$N/A-$1.25-$0.63-100%
2018-09-302018-11-13$N/A-$0.64-$0.57-13.27%
2018-06-302018-08-13$N/A-$2.90-$0.56-422.52%
2018-03-312018-05-14$N/A-$0.71-$0.8617.44%
2017-12-312018-03-08$N/A$2.28-$0.84371.43%
2017-09-302017-11-13$N/A-$1.99-$3.4842.86%
2017-06-302017-08-14$N/A-$7.17-$5.28-35.73%
2017-03-312017-05-11$N/A-$5.40
2016-12-312017-03-16$N/A-$12.96-$10.92-18.68%
2016-09-302016-11-14$N/A$0.84-$15.36105.47%
2016-06-302016-08-12$N/A-$9.00-$12.6028.57%
2016-03-312016-05-05$N/A-$13.30
2015-12-312016-03-30$-5337911-$10.80-$27.0060%
2015-09-302015-11-12$772244-$27.02
2015-06-302015-08-06$2.69 million-$20.45
2015-03-312015-05-13$1.87 million-$24.09
2014-09-302014-11-12$3426-$23.81
2014-06-302014-08-12$10000-$23.49
2014-03-312014-05-14$24000-$18.00-$19.809.09%
2013-12-312014-03-27$48000-$27.00-$34.2021.05%
2013-09-302013-11-12$76000-$39.60-$22.50-76%
2013-06-302013-08-14$327000-$30.60-$25.20-21.43%
2013-03-312013-05-15$182000-$25.20-$18.00-40%
2012-12-312013-03-28$99000-$19.80-$19.800%
2012-09-302012-12-20$105000-$18.28

Atossa Therapeutics, Inc (ATOS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Atossa Therapeutics, Inc (ATOS) Chart:

Atossa Therapeutics, Inc (ATOS) News:

Below you will find a list of latest news for Atossa Therapeutics, Inc (ATOS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Atossa Therapeutics, Inc (ATOS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-08-2110CALL0 0366.23TRUE00
2026-08-2120CALL0 12246.81TRUE00
2026-08-2130CALL0 42137.78FALSE00
2026-08-2140CALL0 0472.81FALSE00
2026-08-2150CALL0 6246.69FALSE00
2026-08-2160CALL0 2330.02FALSE00
2026-08-2110PUT0 1299.9FALSE00
2026-08-2120.05PUT0 89124.18FALSE00
2026-08-2130PUT0 1112.85TRUE00
2026-08-2140PUT0 0172.52TRUE00
2026-08-2150PUT0 0195.89TRUE00
2026-08-2160PUT0 0227.96TRUE00
2026-09-1810CALL0 0194.36TRUE00
2026-09-1820CALL0 0158.47TRUE00
2026-09-1830CALL0 2244.45FALSE00
2026-09-1840CALL0 0254.03FALSE00
2026-09-1850CALL0 0289.34FALSE00
2026-09-1860CALL0 0316.1FALSE00
2026-09-1810PUT0 0324.2FALSE00
2026-09-1820PUT0 0168.8FALSE00
2026-09-1830.95PUT1 0114.79TRUE0.950
2026-09-1840PUT0 0106.19TRUE00
2026-09-1850PUT0 0181.26TRUE00
2026-09-1860PUT0 0206.08TRUE00
2026-10-1610CALL0 0185.56TRUE00
2026-10-1620.45CALL3 4483.27TRUE0.450
2026-10-1630CALL0 59133.44FALSE00
2026-10-1640CALL0 25158.5FALSE00
2026-10-1650CALL0 12138.77FALSE00
2026-10-1660CALL0 15291.9FALSE00
2026-10-1670CALL0 31309.23FALSE00
2026-10-1680CALL0 24323.65FALSE00
2026-10-1690CALL0 144335.95FALSE00
2026-10-1610PUT0 0258.32FALSE00
2026-10-1620PUT0 092.8FALSE00
2026-10-1630PUT0 084.27TRUE00
2026-10-1640PUT0 11121.18TRUE00
2026-10-1650PUT0 1111.31TRUE00
2026-10-1660PUT0 0167.77TRUE00
2026-10-1670PUT0 1184.51TRUE00
2026-10-1680PUT0 1198.74TRUE00
2026-10-1690PUT0 0211.14TRUE00
2027-01-1510CALL0 51122.4TRUE00
2027-01-1520.95CALL0 106112.15TRUE00
2027-01-1530CALL0 18134.2FALSE00
2027-01-1540CALL0 54295.35FALSE00
2027-01-1550.1CALL0 58181.51FALSE00
2027-01-1560CALL0 4196.14FALSE00
2027-01-1570CALL0 31207.87FALSE00
2027-01-1580CALL0 3217.62FALSE00
2027-01-1590CALL0 1225.95FALSE00
2027-01-15100CALL0 0233.19FALSE00
2027-01-1510PUT0 0223.32FALSE00
2027-01-1520PUT0 0147.86FALSE00
2027-01-1530PUT0 0100.44TRUE00
2027-01-1540PUT0 187.03TRUE00
2027-01-1550PUT0 083.35TRUE00
2027-01-1560PUT0 097.17TRUE00
2027-01-1570PUT0 0108.81TRUE00
2027-01-1580PUT0 0118.9TRUE00
2027-01-1590PUT0 0127.83TRUE00
2027-01-15100PUT0 0135.86TRUE00

Latest ATOS Trades:

Date Shares Price
Jun 13, 2022 7:57 PM EST180$1.055
Jun 13, 2022 7:58 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055

Atossa Therapeutics, Inc (ATOS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011265/0001437749-20-011265-index.htm
2018-04-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018010515/0000000000-18-010515-index.htm
2018-04-25UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018012803/0000000000-18-012803-index.htm
2018-06-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018018066/0000000000-18-018066-index.htm
2020-09-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000020008409/0000000000-20-008409-index.htm
2017-10-31SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000090266417004121/0000902664-17-004121-index.htm
2018-01-19SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000090266418000311/0000902664-18-000311-index.htm
2017-11-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000093041317003736/0000930413-17-003736-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000093041318000510/0000930413-18-000510-index.htm
2018-04-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000121390018005062/0001213900-18-005062-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000121390019001898/0001213900-19-001898-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774918020569/0001437749-18-020569-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774918020638/0001437749-18-020638-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/0001437749-19-000870-index.htm
2019-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000143774919005927/0001437749-19-005927-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919005929/0001437749-19-005929-index.htm
2019-04-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919007053/0001437749-19-007053-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919009664/0001437749-19-009664-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919009666/0001437749-19-009666-index.htm
2019-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010399/0001437749-19-010399-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010644/0001437749-19-010644-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010645/0001437749-19-010645-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010646/0001437749-19-010646-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010647/0001437749-19-010647-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010648/0001437749-19-010648-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919012879/0001437749-19-012879-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919016448/0001437749-19-016448-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919016451/0001437749-19-016451-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919020029/0001437749-19-020029-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919022613/0001437749-19-022613-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919022614/0001437749-19-022614-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920000245/0001437749-20-000245-index.htm
2020-02-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920002083/0001437749-20-002083-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920002085/0001437749-20-002085-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920006154/0001437749-20-006154-index.htm
2020-03-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000143774920006155/0001437749-20-006155-index.htm
2020-04-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007556/0001437749-20-007556-index.htm
2020-04-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007600/0001437749-20-007600-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007628/0001437749-20-007628-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007630/0001437749-20-007630-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920010512/0001437749-20-010512-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920010514/0001437749-20-010514-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011257/0001437749-20-011257-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011261/0001437749-20-011261-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011262/0001437749-20-011262-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011263/0001437749-20-011263-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011264/0001437749-20-011264-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011265/0001437749-20-011265-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920017737/0001437749-20-017737-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920017738/0001437749-20-017738-index.htm
2020-09-02S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000143774920019223/0001437749-20-019223-index.htm
2020-09-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000143774920019381/0001437749-20-019381-index.htm
2020-09-25424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920020266/0001437749-20-020266-index.htm
2020-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920020267/0001437749-20-020267-index.htm
2017-11-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000155335017001165/0001553350-17-001165-index.htm
2017-11-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000155335017001167/0001553350-17-001167-index.htm
2017-10-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417005904/0001615774-17-005904-index.htm
2017-10-27424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417005964/0001615774-17-005964-index.htm
2017-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417005989/0001615774-17-005989-index.htm
2017-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417006519/0001615774-17-006519-index.htm
2017-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417006627/0001615774-17-006627-index.htm
2017-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm
2017-12-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417007507/0001615774-17-007507-index.htm
2017-12-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/0001615774-17-007555-index.htm
2018-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418000770/0001615774-18-000770-index.htm
2018-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001342/0001615774-18-001342-index.htm
2018-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001692/0001615774-18-001692-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000161577418001693/0001615774-18-001693-index.htm
2018-03-08PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001705/0001615774-18-001705-index.htm
2018-03-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001985/0001615774-18-001985-index.htm
2018-03-27S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418002120/0001615774-18-002120-index.htm
2018-04-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002285/0001615774-18-002285-index.htm
2018-04-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002644/0001615774-18-002644-index.htm
2018-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002666/0001615774-18-002666-index.htm
2018-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002808/0001615774-18-002808-index.htm
2018-04-23S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/0001615774-18-002813-index.htm
2018-04-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002815/0001615774-18-002815-index.htm
2018-05-03S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418003227/0001615774-18-003227-index.htm
2018-05-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003229/0001615774-18-003229-index.htm
2018-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003390/0001615774-18-003390-index.htm
2018-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003391/0001615774-18-003391-index.htm
2018-05-10424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418003583/0001615774-18-003583-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418003668/0001615774-18-003668-index.htm
2018-05-16FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003930/0001615774-18-003930-index.htm
2018-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003978/0001615774-18-003978-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004587/0001615774-18-004587-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004655/0001615774-18-004655-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004657/0001615774-18-004657-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004659/0001615774-18-004659-index.htm
2018-06-04S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418004829/0001615774-18-004829-index.htm
2018-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005158/0001615774-18-005158-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005994/0001615774-18-005994-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005995/0001615774-18-005995-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005996/0001615774-18-005996-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005997/0001615774-18-005997-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005998/0001615774-18-005998-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006000/0001615774-18-006000-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006001/0001615774-18-006001-index.htm
2018-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006119/0001615774-18-006119-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418007922/0001615774-18-007922-index.htm
2018-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418007923/0001615774-18-007923-index.htm
2018-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418009490/0001615774-18-009490-index.htm
2018-11-1310-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418012549/0001615774-18-012549-index.htm
2019-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577419000644/0001615774-19-000644-index.htm
2019-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577419000645/0001615774-19-000645-index.htm
2018-05-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999518001185/9999999995-18-001185-index.htm
2018-06-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999518001509/9999999995-18-001509-index.htm
2020-09-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999520002415/9999999995-20-002415-index.htm

Atossa Therapeutics, Inc (ATOS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Atossa Therapeutics, Inc (ATOS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 12%
Institutional Ownership: 649%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-11-15Kyle GuseCFO, Gen Counsel and SecretaryBuy1,400.000.34471.1010,000.00https://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm
2017-11-15Kyle GuseCFO, Gen Counsel and SecretaryBuy8,600.000.342,898.208,600.00https://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm